Dimensional Fund Advisors LP Increases Position in Alexion Pharmaceuticals, Inc. (ALXN)
Dimensional Fund Advisors LP increased its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 4.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 321,459 shares of the biopharmaceutical company’s stock after buying an additional 13,679 shares during the period. Dimensional Fund Advisors LP’s holdings in Alexion Pharmaceuticals were worth $38,975,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Guardian Life Insurance Co. of America raised its position in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Alexion Pharmaceuticals during the first quarter worth about $111,000. Independent Portfolio Consultants Inc. raised its position in Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 340 shares during the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co raised its position in Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 100 shares during the last quarter. Finally, Princeton Alpha Management LP bought a new position in Alexion Pharmaceuticals during the first quarter worth about $219,000. 90.74% of the stock is currently owned by institutional investors and hedge funds.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down 0.91% during trading on Friday, reaching $133.40. The company had a trading volume of 1,416,434 shares. The firm has a market capitalization of $29.77 billion, a price-to-earnings ratio of 57.85 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $145.42. The stock has a 50 day moving average price of $130.85 and a 200 day moving average price of $123.13.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The business had revenue of $912 million during the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. Alexion Pharmaceuticals’s revenue was up 21.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.13 earnings per share. On average, equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.
ALXN has been the topic of a number of recent research reports. TheStreet raised Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a report on Friday, July 14th. Deutsche Bank AG dropped their target price on Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $158.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. Leerink Swann reissued a “buy” rating on shares of Alexion Pharmaceuticals in a report on Tuesday, May 23rd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $157.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. Six investment analysts have rated the stock with a hold rating, twenty have given a buy rating and two have assigned a strong buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $156.13.
In other news, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average price of $116.32 per share, with a total value of $156,910,445.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the sale, the director now directly owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The disclosure for this sale can be found here. In the last three months, insiders have purchased 2,019,734 shares of company stock valued at $235,606,846. Insiders own 4.35% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.